专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20170252430A1 POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT 审中-公开
公开(公告)号：US20170252430A1
公开(公告)日：2017-09-07
申请号：US15300682
申请日：2015-04-01
申请人： CUREVAC AG
发明人： Mariola FOTIN-MLECZEK , Regina HEIDENREICH
IPC分类号： A61K39/385 , A61K39/155 , A61K39/205 , A61K39/145 , C12N15/117 , C12N7/00
CPC分类号： A61K39/385 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/205 , A61K47/6455 , A61K2039/53 , A61K2039/552 , A61K2039/55516 , A61K2039/55561 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/6093 , A61K2039/622 , C12N7/00 , C12N15/117 , C12N2310/17 , C12N2320/31 , C12N2320/32 , C12N2760/16134 , C12N2760/16171 , C12N2760/18534 , C12N2760/18571 , C12N2760/20134 , C12N2760/20171
摘要： The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. The present invention also provides pharmaceutical compositions, particularly vaccines, comprising the inventive polymeric carrier cargo complex and the second nucleic acid molecule, as well as the use of the inventive polymeric carrier cargo complex and the second nucleic acid molecule for transfecting a cell, a tissue or an organism, as a medicament, for therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned herein. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and the second nucleic acid molecule, the inventive pharmaceutical composition and/or the inventive vaccine or any of its components in one or more parts of the kit.

52. 发明申请

US20170247699A1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION 审中-公开
公开(公告)号：US20170247699A1
公开(公告)日：2017-08-31
申请号：US15590370
申请日：2017-05-09
申请人： CureVac AG
发明人： Andreas THESS
IPC分类号： C12N15/113 , A61K48/00 , A61K39/00 , C12N15/85
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.

53. 发明申请

US20170218030A1 RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE 审中-公开
公开(公告)号：US20170218030A1
公开(公告)日：2017-08-03
申请号：US15488815
申请日：2017-04-17
申请人： CureVac AG
发明人： Thomas KRAMPS , Margit SCHNEE , Daniel VOSS , Benjamin PETSCH
IPC分类号： C07K14/005 , C07K16/10 , C12N7/00 , A61K39/155
CPC分类号： C07K14/005 , A61K39/12 , A61K39/155 , A61K48/00 , A61K2039/505 , A61K2039/53 , A61K2039/6031 , C07K16/1027 , C07K2317/24 , C12N7/00 , C12N2760/18534
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

54. 外观设计

USD787703S1 Inlay for a culture plate 有权
公开(公告)号：USD787703S1
公开(公告)日：2017-05-23
申请号：US29562502
申请日：2016-04-26
申请人： CureVac AG
设计人： Christian Mayer

55. 发明申请

US20170014496A1 COMBINATION OF VACCINATION AND OX40 AGONISTS 审中-公开
标题翻译：接种和OX40激素的组合
公开(公告)号：US20170014496A1
公开(公告)日：2017-01-19
申请号：US15124822
申请日：2014-03-12
申请人： CUREVAC AG
发明人： Mariola FOTIN-MLECZEK , Karl-Josef KALLEN , Jan C. SCHMOLLINGER
IPC分类号： A61K39/00 , C07K16/30 , C07K16/28 , A61K39/395
CPC分类号： A61K39/0011 , A61K39/39 , A61K39/39558 , A61K2039/505 , A61K2039/53 , A61K2039/55516 , C07K16/2878 , C07K16/30 , C07K2319/00 , C07K2319/30 , Y02A50/403 , Y02A50/412 , Y02A50/416 , Y02A50/466 , Y02A50/47 , Y02A50/487 , Y02A50/489 , A61K2300/00
摘要： The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
摘要翻译：本发明涉及包含RNA疫苗的疫苗/激动剂组合，所述RNA疫苗包含至少一种包含编码至少一种抗原的开放阅读框（ORF）和包含至少一种OX40激动剂的组合物的RNA。本发明还涉及包含这种疫苗/激动剂组合的组分的药物组合物和试剂盒。另外，本发明涉及这种疫苗/激动剂组合的医学用途，药物组合物和包含这种疫苗/激动剂组合的部分试剂盒，特别是用于预防或治疗肿瘤或癌症疾病或感染性疾病。此外，本发明涉及RNA疫苗在与OX40激动剂组合的治疗中的用途。

56. 发明申请

US20170000871A1 COMPOSITION FOR TREATING PROSTATE CANCER (PCa) 审中-公开
标题翻译：治疗前列腺癌（PCa）的组合物
公开(公告)号：US20170000871A1
公开(公告)日：2017-01-05
申请号：US15271122
申请日：2016-09-20
申请人： CureVac AG
发明人： Jochen PROBST , Ingmar HOERR , Thomas LANDER
IPC分类号： A61K39/00 , A61K39/39
CPC分类号： A61K39/0011 , A61K39/00 , A61K39/39 , A61K2039/53 , A61K2039/55516 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译：本发明涉及包含至少一种RNA的活性（免疫刺激性）组合物，优选mRNA，编码能够在哺乳动物中引发（适应性）免疫应答的至少两种（优选不同的）抗原，其中抗原选自 PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）。本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗，治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

57. 发明申请

US20160367704A1 COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION 审中-公开
标题翻译： RNA和阳离子肽的复制用于转移和免疫
公开(公告)号：US20160367704A1
公开(公告)日：2016-12-22
申请号：US15228932
申请日：2016-08-04
申请人： CureVac AG
发明人： Mariola FOTIN-MLECZEK , Patrick BAUMHOF
IPC分类号： A61K48/00 , C12N9/02
CPC分类号： A61K48/005 , A61K9/0019 , A61K38/45 , A61K38/4846 , A61K39/00 , A61K47/61 , A61K47/6455 , A61K48/0033 , A61K48/0041 , A61K48/0066 , A61K48/0075 , A61K2039/53 , C07K19/00 , C12N9/0069 , C12N15/87 , C12Y113/12007 , C12Y204/01007 , C12Y304/21022
摘要： The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(Lys)m;(His)n;(Om)o;(Xaa)x with the majority of residues being selected from Arg, Lys, His, Om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.
摘要翻译：本发明涉及复合RNA，其包含与一种或多种寡肽复合的至少一种RNA，其中具有细胞穿透肽（CPP）功能的寡肽具有8至15个氨基酸的长度，并且具有经验式（Arg）l;（Lys）m;（His）n;（Om）o;（Xaa）x，大部分残基选自Arg，Lys，His，Om。本发明还涉及用于转染细胞或生物体的方法，从而应用本发明的复合RNA。此外，本文公开了包含本发明复合RNA的药物组合物和试剂盒，以及本发明的复合RNA用于转染细胞，组织或生物体和/或用于调节，优选诱导或增强免疫应答的用途。

58. 发明申请

US20160304938A1 METHODS FOR RNA ANALYSIS 审中-公开
标题翻译： RNA分析方法
公开(公告)号：US20160304938A1
公开(公告)日：2016-10-20
申请号：US15195901
申请日：2016-06-28
申请人： CureVac AG
发明人： Aniela WOCHNER
IPC分类号： C12Q1/68 , B01D15/32 , B01D15/16 , C07H21/02 , G01N30/88
CPC分类号： C12Q1/6806 , B01D15/163 , B01D15/325 , C07H21/02 , G01N30/88 , G01N2030/8827 , C12Q2521/337 , C12Q2565/137 , C12Q2565/125
摘要： The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5′ terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule. In particular, the invention concerns a method for determining the presence of a cap structure in an RNA molecule having a cleavage site for a catalytic nucleic acid molecule, a method for determining the capping degree of a population of RNA molecules having a cleavage site for a catalytic nucleic acid molecule, a method for determining the orientation of the cap structure in a capped RNA molecule having a cleavage site for a catalytic nucleic acid molecule and a method for determining relative amounts of correctly capped RNA molecules and reverse-capped RNA molecules in a population of RNA molecules, wherein the population comprises correctly capped and/or reverse-capped RNA molecules that have a cleavage site for a catalytic nucleic acid molecule. Moreover, the present invention provides uses of a catalytic nucleic acid molecule.
摘要翻译：本发明涉及RNA分析领域。特别地，本发明涉及催化核酸分子用于分析RNA分子的用途。本发明涉及分析具有催化核酸分子切割位点的RNA分子的5'末端结构的方法。特别地，本发明涉及一种确定具有催化核酸分子切割位点的RNA分子中帽结构的存在的方法，确定具有切割位点的RNA分子的封端程度的方法催化核酸分子，用于确定具有催化性核酸分子的切割位点的封端RNA分子中的帽结构的取向的方法，以及用于确定正确加帽的RNA分子和反向封端的RNA分子的相对量的方法 RNA分子的群体，其中群体包含具有催化性核酸分子的切割位点的正确封端和/或反向封端的RNA分子。此外，本发明提供催化核酸分子的用途。

59. 发明申请

US20160303210A1 COMPOSITION FOR TREATING PROSTATE CANCER (PCa) 审中-公开
标题翻译：治疗前列腺癌（PCa）的组合物
公开(公告)号：US20160303210A1
公开(公告)日：2016-10-20
申请号：US15198456
申请日：2016-06-30
申请人： CureVac AG
发明人： Jochen PROBST , Ingmar HOERR , Thomas LANDER
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K39/39 , A61K2039/53 , A61K2039/55516 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译：本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激性）组合物，其编码至少两种（优选不同的）能够在哺乳动物中引发（适应性）免疫应答的抗原，其中所述抗原选自组由PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）组成。本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗，治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。

60. 发明申请

US20160166678A1 COMBINATION VACCINE 审中-公开
标题翻译：组合疫苗
公开(公告)号：US20160166678A1
公开(公告)日：2016-06-16
申请号：US15048561
申请日：2016-02-19
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Daniel VOSS
IPC分类号： A61K39/155 , C07K14/005 , C12N7/00 , A61K39/145
摘要： The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
摘要翻译：本发明涉及疫苗，特别是提供至少第一和第二抗原功能的组合疫苗，所述组合疫苗包含至少一种编码至少一种或多种赋予抗原功能的蛋白质或蛋白质的片段，变体或衍生物的RNA，其中所述第一抗原功能是融合（F）蛋白或衍生自所述病毒副副粘病毒科的融合（F）蛋白的片段，变体或衍生物，所述第二抗原功能是血凝素（HA）蛋白或片段，变体或源自病毒科正粘病毒科的血凝素（HA）蛋白衍生物。此外，本发明涉及包含所述组合疫苗的组分和所述组合疫苗的试剂盒或试剂盒，所述组合疫苗用于预防或治疗疾病的方法，特别是预防或治疗感染性疾病如RSV 和流感。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式